tradmap

DLB Financials Dolby Laboratories, Inc.

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 3.0% per year over the past 5 years.
  • Net income has grown slower than revenue (2.0% vs 3.0% per year).
  • Operating margin has been roughly flat, at 19.6% in the latest year.
  • Free cash flow has grown 9.4% per year over the past 5 years.

Shareholder returns

  • Dividends have been paid for 8 consecutive years, consuming 49.6% of earnings and 29.0% of free cash flow.
  • The dividend has grown 7.4% per year over the past 5 years.
Revenue & net income
$0 $675M $1B 2011 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
0% 45% 90% 2011 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Return on equity & assets (ROE / ROA)
0% 9% 19% 2011 2013 2015 2017 2019 2021 2023 2025
ROEROA
Free cash flow (CFO − capex)
$0 $218M $436M 2011 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $613M $1B 2011 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$611M -$69M $472M $0 2011 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MROEROAFCFTotal debtCash
2025 $1.3B $255M 88.1% 19.6% 9.7% 7.9% $436M $702M
2024 $1.3B $262M 89.0% 20.3% 10.6% 8.4% $297M $482M
2023 $1.3B $201M 88.3% 16.6% 8.5% 6.7% $337M $745M
2022 $1.3B $184M 88.7% 16.5% 8.2% 6.8% $271M $620M
2021 $1.3B $310M 89.9% 26.9% 11.9% 10.0% $393M $1.2B
2020 $1.2B $231M 87.4% 18.8% 9.5% 7.9% $278M $1.1B
2019 $1.2B $255M 87.0% 20.7% 11.1% 9.0% $231M $797M
2018 $1.1B $42M 87.9% 17.4% 1.8% 1.5% $279M $918M
2017 $206M 9.7% 8.1% $278M $634M
2016 $186M 9.4% 8.0% $259M $520M
2015 $181M 10.0% 8.5% $152M $532M
2014 $206M 12.1% 10.4% $286M $568M
2013 $189M 12.8% 10.9% $250M $454M
2012 $264M 15.4% 13.5% $223M $493M
2011 $309M 18.6% 16.4% $356M $552M

Valuation over time

How the market has priced DLB against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 22.9 45.7 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/E
Price / sales (P/S)
0.0 3.4 6.7 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/S
Dividend yield (%)
0.0 1.3 2.5 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
Dividend yield %

Frequently asked questions

Is DLB growing its revenue and profit?

Over the past 5 years, Dolby Laboratories, Inc.'s revenue has grown 3.0% per year, and net income grown 2.0% per year. These are computed facts, not advice.

How much debt does DLB have?

As of FY2025, Dolby Laboratories, Inc. reported — of total debt against $702M of cash.

What is DLB's profit margin?

In FY2025, gross margin was 88.1%, operating margin 19.6%, and net margin 18.9%.

What is DLB's P/E ratio?

As of Sep '26, Dolby Laboratories, Inc. traded at a price-to-earnings ratio of about 23.1× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.